# A Bioequivalence Study of the Fixed Dose Combination Tablets of Canagliflozin and Metformin Extended Release (XR) With Respect to the Individual Components

> **NCT02073227** · PHASE1 · COMPLETED · sponsor: **Janssen Research & Development, LLC** · enrollment: 52 (actual)

## Conditions studied

- Healthy Volunteers

## Interventions

- **DRUG:** Canagliflozin, 300 mg
- **DRUG:** Metformin XR, 500 mg
- **DRUG:** CANA/MET XR FDC, Formulation 1, 150 mg/1,000 mg
- **DRUG:** CANA/MET XR FDC, Formulation 2, 150 mg/1,000 mg

## Key facts

- **NCT ID:** NCT02073227
- **Lead sponsor:** Janssen Research & Development, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-02
- **Primary completion:** 2014-06
- **Final completion:** 2014-06
- **Target enrollment:** 52 (ACTUAL)
- **Last updated:** 2014-09-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02073227

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02073227, "A Bioequivalence Study of the Fixed Dose Combination Tablets of Canagliflozin and Metformin Extended Release (XR) With Respect to the Individual Components". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02073227. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*